Clinical Trial Update: Phase 1/2 Study of Enasidenib (AG-221) in Adults With Advanced Hematologic Malignancies With an Isocitrate Dehydrogenase Isoform 2 (IDH2) Mutation [Phase 1, Phase 2]

View source ↗

Summary

Clinical trial update for Enasidenib (AG-221) in adults with advanced IDH2-mutant hematologic malignancies; Phase 1/2 study completed with results posted.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Hematologic Neoplasms

Drugs mentioned

• Enasidenib (enasidenib)

Snippet

Sponsor: Celgene | Conditions: Hematologic Neoplasms | Phase 1, Phase 2 | Status: COMPLETED | Results posted: 2020-10-23